

## Brilliant Violet 605™ anti-mouse CD11c Antibody

<b>Catalog# / Size</b>	117333 / 125 µL 117334 / 50 µg
<b>Clone</b>	N418
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	αX integrin, integrin αX chain, CR4, p150, ITGAX
<b>Isotype</b>	Armenian Hamster IgG
<b>Description</b>	CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Armenian Hamster
<b>Immunogen</b>	Mouse spleen dendritic cells
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. <b>Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.</b> Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.</p> <p><a href="#">Learn more about Brilliant Violet™.</a></p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
<b>Excitation Laser</b>	Violet Laser (405 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>3</sup> ,

immunohistochemical staining of acetone-fixed frozen sections<sup>3</sup>, immunofluorescence microscopy<sup>5</sup>,  
<sup>9</sup> (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections<sup>10</sup>), and spatial biology  
(IBEX)<sup>22,23</sup>.

## Application References

(PubMed link indicates  
BioLegend citation)

1. Granucci F, et al. 1997. *J. Immunol.* 159:1794.
2. Stokes RW, et al. 1998. *J. Immunol.* 160:5514.
3. Metlay JP, et al. 1990. *J. Exp. Med.* 171:1753. (IHC, IP)
4. Ma XT, et al. 2006. *Cancer Research* 66:1169.
5. Chin RK, et al. 2006. *J. Immunol.* 177:290. (IF)
6. Cervantes-Barragan L, et al. 2007. *Blood* 109:1131. (FC) [PubMed](#)
7. Turnquist HR, et al. 2007. *J. Immunol.* 178:7018. (FC) [PubMed](#)
8. Benson MJ, et al. 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
9. You Y, et al. 2009. *J. Immunol.* 182:7343. (IF) [PubMed](#)
10. Roland CL, et al. 2009. *Mol. Cancer Res.* 8:1761. (IHC, FC) [PubMed](#)
11. Wikstrom M, et al. 2006. *J. Immunol.* 177:913. [PubMed](#)
12. Pericolini E, et al. 2008. *J. Leukocyte Biol.* 83:1286. [PubMed](#)
13. Randall LM, et al. 2008. *Infect. Immun.* 76:3312. [PubMed](#)
14. Fahlen-Yrild L, et al. 2009. *J. Immunol.* 183:5032. [PubMed](#)
15. Osterholzer JJ, et al. 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
17. Eisenach PA, et al. 2010. *J Cell Sci.* 123:4182. [PubMed](#)
18. Leppin K, et al. 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
19. Sakai F, et al. 2014. *PLoS One.* 9:105370. [PubMed](#)
20. Gibbins JD, et al. 2014. *Blood.* 124:2953. [PubMed](#)
21. White CE, et al. 2015. *J Immunol.* 194:697. [PubMed](#)
22. Lu X, et al. 2015. *J Immunol.* 194:2011. [PubMed](#)
23. Radtke AJ, et al. 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
24. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Bruand M, et al. 2021. *Cell Reports.* 36(3):109412. [PubMed](#)
2. Miranda K, et al. 2022. *iScience.* 25:104994. [PubMed](#)
3. Bergot AS, et al. 2020. *J Immunol.* 204:1787. [PubMed](#)
4. Wong Fok Lung T, et al. 2020. *Nat Microbiol.* 141:5. [PubMed](#)
5. Hulsebus HJ, et al. 2022. *Front Immunol.* 13:884719. [PubMed](#)
6. Minutti CM, et al. 2019. *Immunity.* 50:645. [PubMed](#)
7. Manivasagam S, et al. 2022. *J Immunol.* 208:1341. [PubMed](#)
8. Sepe JJ, et al. 2022. *JACC Basic Transl Sci.* 7:915. [PubMed](#)
9. Park JG, et al. 2021. *iScience.* 24(9):102941. [PubMed](#)
10. de Mingo Pulido, et al. 2021. *Immunity.* 54(6):1154-1167.e7. [PubMed](#)
11. Piper CJM, et al. 2020. *Cell Reports.* 29(7):1878-1892.e7. [PubMed](#)
12. Chow MT, et al. 2019. *Immunity.* 50(6):1498-1512. [PubMed](#)
13. Álvaro de Mingo Pulido et al. 2018. *Cancer cell.* 33(1):60-74. [PubMed](#)
14. Chen J, et al. 2022. *Nat Commun.* 13:6759. [PubMed](#)
15. Stolp B, et al. 2022. *Cell Rep.* 38:110387. [PubMed](#)
16. Xu AQ, et al. 2020. *Elife.* 9:00. [PubMed](#)
17. Almutairi F, et al. 2021. *Front Immunol.* 12:772288. [PubMed](#)
18. Magod P, et al. 2021. *Cell Reports.* 36(5):109480. [PubMed](#)
19. Perner C, et al. 2020. *Immunity.* 53(5):1063-1077.e7. [PubMed](#)
20. Ellis G, et al. 2015. *EMBO Rep.* 16: 1203-1218. [PubMed](#)
21. Kienzl M, et al. 2020. *Oncoimmunology.* 9:1776059. [PubMed](#)
22. Mastandrea I, et al. 2022. *STAR Protoc.* 3:101106. [PubMed](#)
23. Dodagatta-Marri E, et al. 2021. *Cell Rep.* 36:109309. [PubMed](#)
24. Wiesner D, et al. 2015. *PLoS Pathog.* 11:1004701. [PubMed](#)
25. Ratitong B, et al. 2021. *Cell Reports.* 35(7):109139. [PubMed](#)
26. Li J, et al. 2020. *Cancer Discov.* [PubMed](#)
27. Aegerter H, et al. 2020. *Nat Immunol.* 0.975694444. [PubMed](#)
28. Li J, et al. 2020. *Cancer Immunol Res.* 0.529166667. [PubMed](#)
29. Lagares D, et al. 2017. *Sci Transl Med.* 9:eaal3765. [PubMed](#)
30. McAlpine CS, et al. 2021. *Nature.* 595:701. [PubMed](#)
31. Tomlinson KL, et al. 2021. *Nat Commun.* 12:1399. [PubMed](#)
32. Forbester JL, et al. 2020. *J Virol.* 94:. [PubMed](#)
33. Riquelme SA, et al. 2020. *Cell Metabolism.* 31(6):1091-1106.e6. [PubMed](#)
34. Sutherland TE, et al. 2021. *Frontiers in Immunology.* 12:715209. [PubMed](#)
35. Wang ECE, et al. 2019. *Cell Stem Cell.* 24:654. [PubMed](#)
36. Pereira JA, et al. 2020. *Hum Mol Genet.* 29:1253. [PubMed](#)
37. Li J, et al. 2018. *Immunity.* 49:178. [PubMed](#)
38. Guo Y, et al. 2020. *Cell Host & Microbe.* 28(1):104-116.e4. [PubMed](#)
39. Acker KP, et al. 2019. *iScience.* 19:281. [PubMed](#)
40. Medler TR, et al. 2018. *Cancer cell.* 34(4):561-578. [PubMed](#)
41. Macdougall CE, et al. 2018. *Cell metabolism.* 27(3):588-601. [PubMed](#)
42. Pennock ND, et al. 2018. *J Immunother Cancer.* 0.318055556. [PubMed](#)
43. Jorapur A, et al. 2022. *PLoS Pathog.* 18:e1010200. [PubMed](#)
44. Olson GS, et al. 2021. *Cell Reports.* 35(9):109195. [PubMed](#)
45. Dewi IMW, et al. 2021. *Cell Reports Medicine.* 2(5):100289. [PubMed](#)
46. Pundir P, et al. 2020. *Cell Host & Microbe.* 26(1):114-122. [PubMed](#)
47. Kyburz A, et al. 2019. *J Allergy Clin Immunol.* 143:1496. [PubMed](#)
48. Yu X, et al. 2019. *Nat Commun.* 10:574. [PubMed](#)
49. Becker W, et al. 2021. *J Crohns Colitis.* 15:1032. [PubMed](#)

50. Spix B, *et al.* 2022. Nat Commun. 13:318. [PubMed](#)
51. Gamrekelashvili J, *et al.* 2021. Bio Protoc. 11:e4007. [PubMed](#)
52. Muri J, *et al.* 2020. eLife. 9:e53627. [PubMed](#)
53. Dangaj D, *et al.* 2019. Cancer Cell. 35:885. [PubMed](#)
54. Engblom C, *et al.* 2017. Science. 358:6367. [PubMed](#)
55. Hu X, *et al.* 2021. JCI Insight. 6: [PubMed](#)
56. Teo TH, *et al.* 2018. Nat Commun. 9:3905. [PubMed](#)
57. Dallari S, *et al.* 2021. Cell Host Microbe. 29(6):1014-1029.e8. [PubMed](#)
58. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
59. Nicolas-Boluda A, *et al.* 2021. eLife. 10:00. [PubMed](#)
60. Santopaolo M, *et al.* 2021. Front Immunol. 609406:12. [PubMed](#)
61. Lang JF *et al.* 2019. Nat Commun. 10(1):3415. [PubMed](#)
62. Wang R, *et al.* 2022. J Immunother Cancer. 10: [PubMed](#)
63. Hackstein CP, *et al.* 2022. Nat Commun. 13:7472. [PubMed](#)
64. Fleskens V, *et al.* 2019. Cell Rep. 26:3600. [PubMed](#)
65. Ehrens A, *et al.* 2021. Cell Reports. 34(2):108621. [PubMed](#)
66. Koyama M *et al.* 2019. Immunity. 51(5):885-898. [PubMed](#)
67. Phadke MS, *et al.* 2021. Cancer Immunol Res. 9:554. [PubMed](#)
68. Rappe JCF, *et al.* 2021. J Exp Med. 218: [PubMed](#)
69. Gardner A, *et al.* 2022. J Immunother Cancer. 10: [PubMed](#)
70. Subramanian S, *et al.* 2022. Nat Immunol. 23:458. [PubMed](#)
71. Kastenschmidt JM, *et al.* 2021. Cell Rep. 35:108997. [PubMed](#)
72. Allman W, *et al.* 2015. Proc Natl Acad Sci U S A. 112: 4094 - 4103. [PubMed](#)
73. McGinley AM, *et al.* 2020. Immunity. 52(2):342-356. [PubMed](#)
74. Fearon AE, *et al.* 2021. iScience. 24:103143. [PubMed](#)
75. Celas DP, *et al.* 2022. STAR Protoc. 3:101464. [PubMed](#)
76. Goddery EN, *et al.* 2021. Front Immunol. 12:726421. [PubMed](#)

**RRID** AB\_11204262 (BioLegend Cat. No. 117333)  
 AB\_2562415 (BioLegend Cat. No. 117334)

## Antigen Details

<b>Structure</b>	Integrin $\alpha$ -chain, associates with integrin $\beta_2$ (CD18), 150 kD
<b>Distribution</b>	Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells
<b>Function</b>	Cellular adhesion
<b>Ligand/Receptor</b>	iC3b, fibrinogen
<b>Cell Type</b>	Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
<b>Biology Area</b>	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	Adhesion Molecules, CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen Facts Book Academic Press.</li> <li>2. Springer TA. 1994. <i>Cell</i> 76:301.</li> <li>3. Lopez-Rodriguez C, <i>et al.</i> 1996. <i>J. Immunol.</i> 156:3780.</li> </ol>
<b>Gene ID</b>	<a href="#">16411</a>

## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

APC anti-mouse CD11c, Biotin anti-mouse CD11c, FITC anti-mouse CD11c, PE anti-mouse CD11c, Purified anti-mouse CD11c, Alexa Fluor® 488 anti-mouse CD11c, Alexa Fluor® 647 anti-mouse CD11c, PE/Cyanine5 anti-mouse CD11c, PE/Cyanine7 anti-mouse CD11c, Brilliant Violet 605™ anti-mouse CD11c, Alexa Fluor® 700 anti-mouse CD11c, Pacific Blue™ anti-mouse CD11c, APC/Cyanine7 anti-mouse CD11c, PerCP/Cyanine5.5 anti-mouse CD11c, PerCP anti-mouse CD11c, Brilliant Violet 421™ anti-mouse CD11c, Brilliant Violet 570™ anti-mouse CD11c, Brilliant Violet 785™ anti-mouse CD11c, Brilliant Violet 510™ anti-mouse CD11c, Brilliant Violet 650™ anti-mouse CD11c, Purified anti-mouse CD11c (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD11c, PE/Dazzle™ 594 anti-mouse CD11c, Brilliant Violet 711™ anti-mouse CD11c, APC/Fire™ 750 anti-mouse CD11c, TotalSeq™-A0106 anti-mouse CD11c, Brilliant Violet 750™ anti-mouse CD11c, TotalSeq™-B0106 anti-mouse CD11c, TotalSeq™-C0106 anti-

mouse CD11c, KIRAVIA Blue 520™ anti-mouse CD11c, Spark Blue™ 550 anti-mouse CD11c, Spark NIR™ 685 anti-mouse CD11c, Spark UV™ 387 anti-mouse CD11c, Spark Red™ 718 anti-mouse CD11c

## Product Data

---



C57BL/6 mouse splenocytes were stained with I-A/I-E FITC and CD11c (clone N418) Brilliant Violet 605™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587